Ypsomed Holding AG

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CH0019396990
CHF
293.00
165.5 (129.8%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CHF 4,354 Million ()

stock-summary
P/E

48.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.69%

stock-summary
Debt Equity

0.09

stock-summary
Return on Equity

24.03%

stock-summary
Price to Book

5.39

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
129.8%
0%
129.8%
6 Months
129.8%
0%
129.8%
1 Year
129.8%
0%
129.8%
2 Years
113.48%
0%
113.48%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Ypsomed Holding AG for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
14.36%
EBIT Growth (5y)
95.33%
EBIT to Interest (avg)
12.32
Debt to EBITDA (avg)
1.99
Net Debt to Equity (avg)
0.49
Sales to Capital Employed (avg)
0.70
Tax Ratio
16.12%
Dividend Payout Ratio
34.31%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
6.53%
ROE (avg)
8.42%

Valuation key factors

Factor
Value
P/E Ratio
48
Industry P/E
Price to Book Value
6.18
EV to EBIT
34.05
EV to EBITDA
21.27
EV to Capital Employed
4.48
EV to Sales
6.05
PEG Ratio
4.12
Dividend Yield
0.72%
ROCE (Latest)
13.16%
ROE (Latest)
12.87%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Ypsomed Holding AG"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2023 is 7.04% vs 15.14% in Mar 2022",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2023 is 122.08% vs 298.28% in Mar 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'23",
        "Mar'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "497.50",
          "val2": "464.80",
          "chgp": "7.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "115.90",
          "val2": "92.50",
          "chgp": "25.30%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.30",
          "val2": "2.30",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "51.30",
          "val2": "23.10",
          "chgp": "122.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "75.00%",
          "val2": "52.50%",
          "chgp": "2.25%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Mar'23stock-summary

Mar'23
Mar'22
Change(%)
Net Sales
497.50
464.80
7.04%
Operating Profit (PBDIT) excl Other Income
115.90
92.50
25.30%
Interest
2.30
2.30
Exceptional Items
0.00
0.00
Consolidate Net Profit
51.30
23.10
122.08%
Operating Profit Margin (Excl OI)
75.00%
52.50%
2.25%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2023 is 7.04% vs 15.14% in Mar 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2023 is 122.08% vs 298.28% in Mar 2022

stock-summaryCompany CV
About Ypsomed Holding AG stock-summary
stock-summary
Ypsomed Holding AG
Pharmaceuticals & Biotechnology
Ypsomed Holding AG is a Switzerland-based holding company engaged in the manufacture of injection pens for pharmaceutical and biotech companies. The Company develops and manufactures injection systems for custom-made self-administration, and markets pen needles for the treatment of diabetes, growth disorders or infertility, as well as therapeutic areas. The Company operates two business segments: Injection Systems and Diabetes Care. In the Injection Systems segment, the Company's YDS Ypsomed Delivery Systems offer a range of ready-to-use injection systems for pharmaceutical and biotech companies to administer of drugs or to develop and manufacture them in line with customer requirements. The Diabetes Care segment markets products such as pen needles or insulin pump to diabetics, doctors and health insurance providers. The Company operates its production sites in Burgdorf, Solothurn, Grenchen and Tabor, and sales and distribution network across Europe.
Company Coordinates stock-summary
Company Details
Brunnmattstrasse 6 , BURGDORF None : 3401
stock-summary
Tel: 41 34 424411141 34 4243555
stock-summary
stock-summary
Registrar Details